Belgium· BE-AMP-SAM310064-00
Nevanac 1 mg/ml
A nepafenac product containing nepafenac, registered in Belgium by Novartis Europharm. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Nepafenac is registered in 14 of 19 countries.
Countries holding a registration under ATC S01BC10 (nepafenac), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Nepafenac · ATC S01BC10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Nepafenac
- Manufacturer
- Novartis Europharm
- Country
- Belgium (BE)
- ATC code
- S01BC10
- ATC class
- Nepafenac
- Defined daily dose
- 0.15 mg, AT
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for nepafenac.
Graded by severity as the source publishes them — 81 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nepafenac · interactions on record
81 records
- 81 moderate
Most severe, free to view
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- HeparinB01AB01moderate
- Antithrombin IIIB01AB02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nepafenac in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayNevanacNovartis Pharma GmbH
- FinlandNevanacNovartis Europharm Limited
- IrelandNevanac 1 mg/ml Eye drops, suspensionNovartis Europharm Limited
- IcelandNevanacNovartis Europharm Limited*
- NetherlandsNevanac 1 mg/ml oogdruppels, suspensieNovartis Europharm Limited
- PolandNevanacNovartis Europharm Limited
- SwedenNEVANAC 1 mg/ml Ögondroppar, suspensionNovartis Europharm Limited
- CzechiaNEVANACNovartis Europharm Limited, Dublin
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Bulgaria · Апфекто
- Iceland · Nevanac
- Liechtenstein · Nevanac
- Norway · Nevanac
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/15ba816d-ec53-4eb2-9aaf-d9364f4036ce GET /v1/drugs/15ba816d-ec53-4eb2-9aaf-d9364f4036ce?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Eye drops, suspension",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Nevanac 1 mg/ml",
"name_fr": "Nevanac 1 mg/ml",
"name_nl": "Nevanac 1 mg/ml",
"amp_code": "SAM310064-00",
"strengths": [
"1.0000"
],
"pack_count": 1,
"substances": [
"Nepafenac"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Nepafenac",
"authorisation_numbers": [
"EU/1/07/433/001"
]
}See everything about nepafenac.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.